血清促生长激素释放激素受体配体与多囊卵巢综合征的相关性分析

目的:探讨血清促生长激素释放激素受体配体(Ghrelin)水平在多囊卵巢综合征(PCOS)中的意义.方法:选择我院PCOS患者48例作为研究对象(PCOS组),同期选择非PCOS患者40例作为对照(对照组),根据体重指数(IBM)将PCOS组、对照组患者分别分为肥胖与非肥胖,根据稳态模型胰岛素抵抗指数(HOMA-IR)将PCOS组及全部患者分为胰岛素抵抗(IR)与非IR.测定血清Ghrelin水平及内分泌代谢指标.结果:血清Ghrelin水平PCOS组低于对照组(P<0.05);肥胖组低于非肥胖组(P<0.05);非肥胖组低于非肥胖对照组(P<0.05);IR组低于非IR组(P<0.05).血清Ghrelin水平与BMI、空腹胰岛素(FINS)、HOMA-IR呈负相关(P<0.01,P<0.05,P<0.05),与胰岛素敏感指数(ISI)呈正相关(P<0.05).结论:PCOS患者存在血清低Ghrelin水平,Ghrelin水平与BMI、IR程度呈负相关.Ghrelin可能与PCOS的肥胖发生有相关性.血清Ghrelin检测可能作为预测PCOS患者IR的一个指标.     

多囊卵巢综合征患者血清中血管生成素相关生长因子水平的评价

目的探讨多囊卵巢综合征(PCOS)患者血清中血管生成素相关生长因子(angiopoientin-related growth factor,AGF)水平变化,及AGF与PCOS患者胰岛素抵抗的关系。方法 2010年3月至2011年3月在沧州市中心医院选择67例未合并糖尿病的PCOS患者作为研究组,同期选择112例健康女性作为对照组,测定所有研究对象血清AGF质量浓度及与胰岛素抵抗相关的内分泌代谢指标。结果研究组血清AGF水平显著高于对照组(345.3±38.6)vs.(288.7±33.4)μg/L,P<0.05;PCOS胰岛素抵抗组血清AGF水平显著高于PCOS非胰岛素抵抗组(350.9±29.6)vs.(338.4±31.6)μg/L,P<0.05。AGF与BMI(r=0.23,P<0.05)、胰岛素抵抗(IR)指数(HOMA-IR)(r=0.19,P<0.05)呈正相关,与年龄、低密度脂蛋白(LDL-C)、腰臀比(WHR)、空腹血糖(FBG)、2h糖耐量试验(OGTT)、空腹胰岛素(FINS)无关。结论升高的AGF可能在PCOS患者糖脂代谢紊乱的发生发展过程中发挥作用。     

FGF21在PCOS患者血清中的表达及意义

目的:评价多囊卵巢综合征(PCOS)患者血清中成纤维细胞因子21(FGF21)的表达,初步探讨FGF21在PCOS发病中的作用。方法:研究对象分为PCOS组和正常对照组。PCOS组分为肥胖患者和非肥胖患者。分别用酶联免疫法(ELISA)测定血清FGF21水平;采取磁酶免法测定黄体生成素(LH)、睾酮(T);应用化学发光法检测空腹血糖(FBG)、空腹胰岛素(Ins)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)水平。结果:PCOS组FGF21表达明显高于对照组(P<0.01),并且与体重指数(BMI)、Ins(r=0.423,P<0.01;r=0.341,P<0.05)成正相关;在PCOS组中,肥胖患者血清中的FGF21水平高于非肥胖患者(P<0.05),与IR、LH(r=0.440,P=0.046;r=0.44,P=0.044)成正相关。结论:PCOS患者血清中FGF21水平明显高于对照组,在PCOS组中肥胖患者血清中FGF21水平明显高于非肥胖患者。FGF21有望成为PCOS治疗中的新突破。     

多囊卵巢综合征血浆瘦素的改变及相关影响因素的研究

目的探讨多囊卵巢综合征(PCOS)患者血浆瘦素(leptin)水平的变化及其相关影响因素。方法用放射免疫学方法检测63例PCOS患者血浆leptin、血清泌乳素、促黄体生成素、卵泡刺激素、雌二醇、睾酮、雄烯二酮水平,同时行糖耐量及胰岛素释放实验。用相关分析探讨leptin与体重指数(BMI)、性激素、血糖、胰岛素和胰岛素敏感指数的关系。结果PCOS患者空腹胰岛素(r=0.6,P<0.01)和BMI(r=0.351,P<0.01)与血浆瘦素呈显著正相关,且空腹胰岛素对瘦素的影响更显著。结论瘦素可能与PCOS的胰岛素抵抗、高胰岛素血症密切相关。     

白细胞介素18、白细胞介素1 β与多囊卵巢综合征发病的相关性研究

目的探讨血清炎症因子白细胞介素18(IL-18)、白细胞介素1β(IL-1β)与多囊卵巢综合征(PCOS)发病的关系。方法2006年10月至12月对北京大学第三医院住院的PCOS伴有胰岛素抵抗患者30例、PCOS不伴胰岛素抵抗患者30例及对照组30例,检测血清空腹血糖(FBG)、空腹胰岛素(FINS)、卵泡刺激素(FSH)、黄体生成素(LH)和睾酮(T);酶联免疫吸附试验(ELISA)方法检测血清IL-18、IL-1β。结果PCOS胰岛素抵抗组IL-18为(243.16±64.23)ng/L,IL-1β为(158.49±29.60)ng/L;非胰岛素抵抗组血清IL-18为(174.27±66.78)ng/L,IL-1β为(85.58±29.20)ng/L,均明显高于对照组[(122.44±40.15)ng/L,(45.84±26.64)ng/L],差异有显著性意义(P<0.05);PCOS胰岛素抵抗组血清IL-18、IL-1β明显高于PCOS非胰岛素抵抗组(P<0.05)。PCOS肥胖组IL-18为(274.46±63.58)ng/L、IL-1β为(149.35±35.97)ng/L,明显高于PCOS非肥胖组[(172.47±63.95)ng/L,(96.49±41.55)ng/L](P<0.05)。体重指数(BMI)正常的PCOS组血清IL-18和IL-1β明显高于BMI正常的对照组(P<0.05)。PCOS组血清IL-18、IL-1β与BMI、HomaIR及T呈显著正相关(P<0.05)。结论炎症因子IL-18、IL-1β在PCOS患者血清中明显升高,并且在胰岛素抵抗和肥胖的PCOS患者中升高更为明显。慢性炎症可能参与PCOS的发病,并且与胰岛素抵抗及肥胖有关。     

血清脂联素水平测定在多囊卵巢综合征中的意义

目的:探讨脂联素水平在多囊卵巢综合征(PCOS)中的意义。方法:选择我院PCOS患者48例作为研究对象,同期选择非PCOS患者40例作为对照,分为肥胖组与非肥胖组,胰岛素抵抗组与非胰岛素抵抗组。测定血清脂联素水平及内分泌代谢指标。结果:①PCOS组血清脂联素水平低于对照组(P<0.05);非肥胖PCOS组低于非肥胖对照组(P<0.05);胰岛素抵抗组低于非胰岛素抵抗组(P<0.05)。②血清脂联素水平与体重指数(BMI)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、腰臀比(WHR)、甘油三酯(TG)呈负相关(P<0.01,P<0.05),与葡萄糖胰岛素比值(GIR)、胰岛素敏感指数(ISI)呈正相关(P<0.01)。控制BMI影响后血清脂联素水平仍与HOMA-IR、TG呈负相关(P<0.05),与GIR、ISI呈正相关(P<0.01)。结论:①PCOS患者存在低脂联素血症,脂联素水平与胰岛素抵抗程度呈负相关。②脂联素可以作为PCOS发生糖尿病远期并发症的预测指标。     

多囊卵巢综合征胰岛素抵抗与卵巢局部IGF-I系统的相关性研究

目的探讨卵巢局部胰岛素样生长因子-I(IGF-I)系统在PCOS胰岛素抵抗发病机制中的作用。方法选择30例PCOS胰岛素抵抗患者为研究组,30例输卵管性不孕患者为对照组。测定并比较两组的血清、小卵泡液中IGF-I、胰岛素样生长因子结合球蛋白-1(IGFBP-1)及各项性激素、糖代谢及卵巢超声指标,分析其与各项指标之间的相关性。结果研究组小卵泡液IGF-I高于对照组和其血清水平(P0.01),血清和小卵泡液的IGFBP-1低于对照组(P0.05,P0.01),小卵泡液IGFBP-1水平低于血清(P0.05)。研究组小卵泡液IGF-I与总睾酮(T0)、雌二醇(E2)及卵巢体积(OV)、卵巢总面积(TA)、卵泡数(FN)、空腹胰岛素(FI)和口服葡萄糖后2h胰岛素(2h胰岛素)呈正相关(r分别为0.94、0.51、0.52、0.49、0.65、0.76和0.58,P值均0.05);血清IGF-I与胰岛素敏感指数(ISI)、体重指数(BMI)和腰臀比(WHR)呈正相关(r分别为0.47、0.61和0.58,P0.05),与定量胰岛素敏感指数(QUICKI)呈负相关(r=-0.34,P0.05);研究组小卵泡液及血清IGFBP-1与FINS、2h胰岛素呈负相关(r=-0.48,P0.001;r=-0.39,P0.05;r=0.54,P0.05;r=-0.52,P0.05)。结论 PCOS患者的外周胰岛素抵抗可能通过影响卵巢局部IGF-I系统,刺激卵巢组织产生大量雄激素,导致排卵障碍。     

体质量指数正常的多囊卵巢综合征伴胰岛素抵抗患者的临床特征及胰岛素抵抗影响因素分析

目的:观察体质量指数(BMI)正常的多囊卵巢综合征(PCOS)伴胰岛素抵抗(IR)患者的临床及生化表现,探讨其临床特征及IR的影响因素。方法:收集2015年8月至2016年6月就诊于黑龙江中医药大学附属第一医院妇科门诊的BMI正常(18.5 kg/m~2≤BMI≤23.9 kg/m~2)的PCOS患者116例,其中PCOS伴IR患者50例,PCOS不伴IR患者66例,分析、比较两组的临床特征、性激素水平、糖脂代谢水平,采用Spearman或Pearson相关分析稳态模型胰岛素抵抗指数(HOMA-IR)的影响因素。结果:1PCOS伴IR组患者腰臀比、多毛评分明显高于PCOS不伴IR组患者,差异有统计学意义(P0.05);2PCOS伴IR组患者空腹葡萄糖(FPG)、空腹胰岛素(FINS)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)显著高于PCOS不伴IR组患者,差异有统计学意义(P0.05),PCOS伴IR组患者高密度脂蛋白(HDL)显著低于PCOS不伴IR组患者,差异有统计学意义(P0.05);3对BMI正常的PCOS患者进行相关分析,HOMA-IR与年龄、BMI、卵泡刺激素(FSH)、黄体生成激素(LH)、LH/FSH、睾酮(T)、硫酸脱氢表雄酮(DHEAS)、雄烯二酮(AND)无关(P0.05);与腰臀比(r=0.386)、FPG(r=0.459)、FINS(r=0.981)、TC(r=0.360)、TG(r=0.343)和LDL(r=0.467)呈正相关(P0.01),与性激素结合球蛋白(SHBG)(r=-0.220,P0.05)、HDL(r=-0.288,P0.01)呈负相关。结论:BMI正常的PCOS伴IR患者腰臀比、多毛评分及糖、脂代谢指标较无IR的PCOS患者均有改变。BMI正常的PCOS患者的IR与腰臀比、FPG、FINS、TC、TG、LDL及SHBG、HDL相关。     

肥胖与非肥胖多囊卵巢综合征患者血清肿瘤坏死因子-α(TNF-α)水平的比较

目的:比较肥胖与非肥胖多囊卵巢综合征(PCOS)患者血清肿瘤坏死因子-α(TNF-α)水平的差异。方法:55例PCOS患者,根据体质量指数(BMI)分为肥胖组(BMI>25,n=31)和非肥胖组(BMI≤25,n=24);同期选择50例非PCOS育龄妇女,分为肥胖对照组(BMI>25,n=25)和非肥胖对照组(BMI≤25,n=25)。应用酶联免疫吸附法(ELISA)测定血清TNF-α的含量,分析TNF-α与胰岛素抵抗指数(HOMA-IR)的相关性。结果:PCOS肥胖组与PCOS非肥胖组的TNF-α水平分别显著高于其相应的对照组(P<0.01),PCOS非肥胖组的TNF-α水平也显著高于肥胖对照组(P<0.05)。PCOS肥胖组与PCOS非肥胖组之间的TNF-α水平无显著差异(P>0.05)。PCOS组TNF-α与HOMA-IR呈显著正相关(P<0.05)。结论:肥胖与非肥胖PCOS患者的血清TNF-α水平均升高,可能存在肥胖以外升高TNF-α的途径;TNF-α与PCOS的IR发生有密切联系。     

多囊卵巢综合征患者血清中一氧化氮水平及其相关因素的临床研究

目的探讨多囊卵巢综合征（PCOS）患者血清一氧化氮（NO）水平与其血管并发症的关系。方法采用硝酸还原酶法测定27例PCOS患者（PCOS组）,21例因男方因素或输卵管因素不孕患者（对照组）血清NO水平,测定并计算体重指数（BMI）、腰臀比（WHR）、收缩压（SBP）、舒张压（DBP）、体脂含量、胰岛素抵抗指数（HOMA-IR）、胰岛素敏感指数（IAI）、血清性激素、空腹血糖（FPG）和胰岛素（FINS）水平。结果非肥胖PCOS组的HOMA-IR高于非肥胖对照组,IAI、血清NO水平低于非肥胖对照组,差异均有显著性（P〈0.05）。非肥胖PCOS组IAI明显高于肥胖PCOS组,差异有显著性（P〈0.01）。血清NO水平在PCOS组和其对照组间差异无显著性（P〉0.05）。PCOS组中,血清NO水平与HOMA-IR（r=-0.317,P〈0.05）、体脂含量（r=-0.346,P〈0.05）呈负相关。结论PCOS患者血清NO水平降低,提示PCOS患者可能存在血管内皮功能受损。     

The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS

All the components of the renin-angiotensin system have been identified in the human ovary. Renin plays a major role in folliculogenesis, and possibly in follicular atresia. Polycystic ovary syndrome (PCOS) is characterized by early follicular atresia. We studied whether assessment of plasma renin activity would be useful for diagnosing PCOS and distinguishing PCOS and non-PCOS in oligomenorrheic patients. Patients were divided into three groups: PCOS group (group 1, n = 40), non-PCOS oligomenorrheic group (group 2, n = 30) and ovulatory control group (group 3, n = 30). Plasma renin activity was determined in the early follicular phase of the menstrual cycle. Baseline serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin, insulin, aldosterone and androgens (total testosterone, free testosterone, androstenedione, dehydroepiandrosterone sulfate and 17α hydroxyprogesterone) were determined in all groups. The mean LH level was lower (4.94 ± 4.65 mIU/ml) in control patients than in PCOS patients (12.9 ± 1.75 mIU/ml) and non-PCOS oligomenorrheic patients (10.8 ± 1.65 mIU/ml). There was no statistically significant difference between the groups regarding FSH levels. The mean plasma renin activity was 3.47 ± 0.29 ng/ml in the PCOS group. The mean plasma renin activity was 1.59 ± 0.21 ng/ml the non-PCOS oligomenorrheic group (statistically significiant differrence). There was no statistically significant difference between the non-PCOS oligomenorrheic (1.59 ± 0.21 ng/ml) and control groups (1.2 ± 0.16 ng/ml). Use of plasma renin activity alone as a diagnostic marker in PCOS is not useful, because the clinical findings of PCOS are heterogeneous and the pathogenesis is unclear. However, it can be used together with other variables to diagnose women with PCOS and to distinguish non-PCOS oligomenorrheic women from those with PCOS.     

The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS.

All the components of the renin-angiotensin system have been identified in the human ovary. Renin plays a major role in folliculogenesis, and possibly in follicular atresia. Polycystic ovary syndrome (PCOS) is characterized by early follicular atresia. We studied whether assessment of plasma renin activity would be useful for diagnosing PCOS and distinguishing PCOS and non-PCOS in oligomenorrheic patients. Patients were divided into three groups: PCOS group (group 1, n = 40), non-PCOS oligomenorrheic group (group 2, n = 30) and ovulatory control group (group 3, n = 30). Plasma renin activity was determined in the early follicular phase of the menstrual cycle. Baseline serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin, insulin, aldosterone and androgens (total testosterone, free testosterone, androstenedione, dehydroepiandrosterone sulfate and 17alpha hydroxyprogesterone) were determined in all groups. The mean LH level was lower (4.94 +/- 4.65 mIU/ml) in control patients than in PCOS patients (12.9 +/- 1.75 mIU/ml) and non-PCOS oligomenorrheic patients (10.8 +/- 1.65 mIU/ml). There was no statistically significant difference between the groups regarding FSH levels. The mean plasma renin activity was 3.47 +/- 0.29 ng/ml in the PCOS group. The mean plasma renin activity was 1.59 +/- 0.21 ng/ml the non-PCOS oligomenorrheic group (statistically significiant differrence). There was no statistically significant difference between the non-PCOS oligomenorrheic (1.59 +/- 0.21 ng/ml) and control groups (1.2 +/- 0.16 ng/ml). Use of plasma renin activity alone as a diagnostic marker in PCOS is not useful, because the clinical findings of PCOS are heterogeneous and the pathogenesis is unclear. However, it can be used together with other variables to diagnose women with PCOS and to distinguish non-PCOS oligomenorrheic women from those with PCOS.     

多囊卵巢综合征患者妊娠期胰岛素抵抗及妊娠结局观察分析

目的探讨多囊卵巢综合征(PCOS)患者妊娠期胰岛素抵抗的变化及与妊娠结局的关系。方法选择2007年9月至2009年2月在中山大学孙逸仙纪念医院妇产科确诊为PCOS并妊娠成功的102例孕妇为PCOS组,同期在本院早孕检查、产检及分娩的普通孕产妇701例为对照组,比较两组孕妇的妊娠并发症及妊娠结局。对PCOS组中的38例及对照组中的50例孕妇于24～28周进行75g葡萄糖耐量检查及胰岛素释放试验,计算胰岛素抵抗指数(HOMA-IR)、胰岛β细胞分泌功能指数(HOMA-β)、血糖和胰岛素曲线下面积。结果 PCOS组血糖曲线下面积及胰岛素曲线下面积大于对照组(22.22±4.48、19.29±3.19,228.93±130.05、155.62±69.54,P<0.05);PCOS组空腹血糖、空腹胰岛素、HOMA-IR、HOMA-β大于对照组,分别为4.61±0.57、4.56±0.39,7.81±4.65、6.35±4.45,1.65±1.08、1.31±0.95,169.47±119.4、126.94±85.81,但差异无统计学意义。PCOS组与对照组妊娠并发症发生率分别为自然流产23.53%、8.27%,妊娠期糖...     

多囊卵巢综合征患者脂联素、C反应蛋白水平的变化及其意义

目的:探讨脂联素(APN)、C反应蛋白(CRP)的变化对多囊卵巢综合征(PCOS)发病的意义。方法:按体重指数(BMI≥25kg/m2或<25kg/m2)分别将PCOS患者52例、对照组47例分为PCOS肥胖组(25例)、非肥胖组(27例)和对照肥胖组(23例)、对照非肥胖组(24例)4组。用ELISA法测定4组的APN水平、散射比浊法测CRP水平,葡萄糖氧化酶法测定空腹血糖(FPG)、化学发光法测空腹胰岛素(FIN)水平,并计算胰岛素抵抗指数(HOMA-IR)。结果:①PCOS组APN水平低于对照组(P<0.05),且同组肥胖者低于非肥胖者。②PCOS组CRP水平高于对照组(P<0.05),且肥胖者高于非肥胖者。③APN水平与BMI、HOMA-IR水平呈明显负相关(P<0.05)。结论:PCOS组APN水平降低,CRP水平升高,且以肥胖者明显。APN水平降低、CRP水平升高与PCOS患者胰岛素抵抗密切相关。     

Effects of kisspeptin on pathogenesis and energy metabolism in polycystic ovarian syndrome (PCOS)

Kisspeptin has been shown to participate in the regulation of pituitary hormone secretion and energy metabolism. In PCOS patients, there are disorders in pituitary hormone secretion and energy metabolism. The aim of this study was to investigate the serum kisspeptin and its relationship with abnormal metabolism in PCOS. This restrospective case–control study included 73 cases with PCOS and 63 control cases. All subjects were divided into obese and nonobese groups based on BMI. The serum kisspeptin levels, Cor, DHEA-S, plasma concentrations of glucose were tested. We found that the level of kisspeptin in PCOS group was higher than it in control group. The kisspeptin levels in nonobese PCOS group increased most obviously over than the other groups. The kisspeptin levels of all the subjects were positively correlated with LH levels, negatively correlated with the glucose-AUC, the insulin-AUC, and triglyceride levels. The findings of this study suggest that kisspeptin may play an important role in ovulation disorders in PCOS patients through regulating the level of LH and it could regulate the body's energy metabolism by regulating glucose and lipid metabolism.     

MIF和子痫前期炎症反应机制的关系

目的研究子痫前期胎盘组织炎症反应情况及巨噬细胞移动抑制因子（MIF）的表达,探讨MIF在子痫前期炎症反应中的作用。方法选取住院分娩的子痫前期孕产妇53例,其中轻度子痫前期孕产妇25例（轻度子痫前期组）,重度子痫前期孕产妇28例（重度子痫前期组）。另选取同期正常妊娠晚期孕产妇30例为对照组。采用逆转录（RT）PCR技术检测三组孕产妇胎盘组织中MIFmRNA的表达;采用免疫比浊法检测三组孕产妇血浆中CRP水平;采用ELISA方法检测三组孕产妇血浆中（TNF-α）、IL-6浓度。并对轻度及重度子痫前期组孕产妇血浆中CRP水平与胎盘组织中MIFmRNA表达的相关性进行分析。结果①三组孕产妇胎盘组织中均有MIF的表达,轻度子痫前期组孕产妇胎盘组织中MIFmRNA的水平为（0.84±0.13）,重度子痫前期组为（1.05±0.11）,两组比较,差异有统计学意义（P〈0.01）。对照组孕产妇胎盘组织中MIFmRNA为（0.70±0.12）,明显低于轻度及重度子痫前期组,差异均有统计学意义（P〈0.01）;②轻度子痫前期组孕产妇血浆CRP、（TNF-α）、IL-6浓度分别为（14.99±6.85）mg/L、（14.76±3.67）pg/ml、（24.68±10.13）pg/L,重度子痫前期组孕产妇血浆CRP、（TNF）、IL-6浓度分别为（21.16±8.89）mg/L、（19.66±6.13）pg/ml、（30.91±14.34）pg/L,差异有统计学意义（P〈0.01）;对照组孕产妇血浆CRP、（TNF）、IL-6浓度分别为（4.71±1.76）mg/L、（9.94±2.53）pg/ml、（14.14±5.06）pg/L,明显低于轻度及重度子痫前期组,差异有统计学意义（P〈0.01）;③轻度及重度子痫前期组孕产妇血浆中CRP水平与胎盘组织中MIFmRNA表达水平呈正相关（r=0.67,P〈0.01）。结论子痫前期患者胎盘组织中的MIF的过度表达,可上调血浆中炎性标志物CRP的水平,引起血管内皮损伤,从而参与子痫前期的发病。     

Influence of insulin resistance on total renin level in normotensive women with polycystic ovary syndrome

OBJECTIVE: To evaluate the influence of insulin resistance on the plasma total renin level in normotensive women with polycystic ovary syndrome (PCOS). DESIGN: Prospective, controlled study. SETTING: University hospital. PATIENT(S): Twenty-five normotensive women with PCOS were compared with 11 normotensive control women with regular cycles and no features of PCOS. INTERVENTION(S): Clinical, ultrasonographic, and hormonal findings were used to define PCOS. Insulin resistance was estimated by continuous infusion of glucose with model assessment in the early follicular phase. MAIN OUTCOME MEASURE(S): Plasma levels of total renin and angiotensin II and serum levels of gonadotropins, DHEAS, total T, free T, 17 alpha-hydroxyprogesterone, and PRL were determined. RESULT(S): Plasma concentrations of angiotensin II were similar in the PCOS group and the control group. The concentration of total renin in plasma was higher in women with PCOS than in healthy women independent of insulin resistance. The sensitivity and specificity of the plasma total renin level to diagnose women with PCOS were calculated as 80% and 71.4%, respectively. CONCLUSION(S): The plasma total renin level is higher in normotensive women with PCOS than in healthy women independent of insulin resistance.     

Evaluation of dopaminergic activity of the hypothalamus in patients with polycystic ovarian syndrome]

To evaluate the hypothalamic dopaminergic activity in patients with polycystic ovary syndrome (PCOS), we studied the PRL, TSH, LH and FSH responses to i.m. administration of sulpiride in five euthyroid women affected by PCOS and in five normal women. The mean basal PRL and TSH plasma levels resulted significantly higher (p less than 0.01) in PCOS subjects with respect to normal subjects. The incremental area under PRL and TSH profiles, after sulpiride administration, were significantly lower (p less than 0.05) in PCOS patients than in the control group; no significant variation of LH and FSH plasma levels resulted. Our data suggest a decrease dopaminergic activity in PCOS.     

抗苗勒管激素与非肥胖型多囊卵巢综合征合并胰岛素抵抗的关系

目的:探究抗苗勒管激素(AMH)与非肥胖型多囊卵巢综合征(PCOS)合并胰岛素抵抗(IR)的关系。方法:研究纳入102例非肥胖型PCOS患者为PCOS组,其中PCOS合并IR组(n=48),单纯PCOS组(n=54),50名非肥胖型健康人作为对照组。比较3组血清AMH水平以及AMH水平与PCOS合并IR的关系。结果:PCOS合并IR组血清AMH水平和HOMA-IR高于单纯PCOS组和对照组,差异有统计学意义(均P0.001)。PCOS组AMH水平与HOMAIR呈正相关(r=0.704,P0.001)。结论:非肥胖型PCOS患者合并IR血清AMH水平升高,AMH水平与PCOS合并IR相关。     

Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance

Objectives.?The present study was undertaken to investigate the association between plasma visfatin concentrations and inflammatory markers such as interleukin-6 (IL-6) and high-sensitive C-reactive protein (hsCRP) in company with several metabolic parameters in lean women with polycystic ovary syndrome (PCOS).

Methods.?The study group consisted of 21 lean women with PCOS (BMI 20.74 ± 1.74 kg/m²) and 15 healthy, normally menstruating women (BMI 20.85 ± 2.08 kg/m² control group). PCOS was defined according to the Rotterdam criteria. Visfatin, IL-6, hsCRP, hyperandrogenism markers and metabolic markers were examined in all PCOS and control women.

Results.?Plasma visfatin level in the PCOS group was higher than that in the control group. Plasma hsCRP and IL-6 levels in PCOS group were similar with the control group. Plasma visfatin levels were positively associated with total cholesterol, high density lipoprotein, hirsutism score, total testosterone and FAI. Plasma visfatin level was negatively associated with SHBG. However, there were no correlation between plasma visfatin level and IL-6 and hsCRP. In multivariate regression analyses, only FAI and high density lipoprotein-cholesterol (HDL-C) showed a significant association with serum visfatin.

Conclusion. Our data indicates that plasma visfatin levels are associated with HDL-C and markers of hyperandrogenism, but it is not associated with proinflammatory markers and insulin resistance in lean women with PCOS.